González-Moreno, Juan
Dispenzieri, Angela
Grogan, Martha
Coelho, Teresa
Tournev, Ivailo
Waddington-Cruz, Márcia
Wixner, Jonas http://orcid.org/0000-0002-1536-1277
Diemberger, Igor
Garcia-Pavia, Pablo
Chapman, Doug
Gupta, Pritam
Glass, Oliver
Amass, Leslie
Plante-Bordeneuve, Violaine
Conceicao, Isabel
Jeon, Eun-Seok
Maurer, Mathew
Costello, Jose Gonzalez
Lairez, Olivier
Ueda, Mitsuharu
Kristen, Arnt
Sekijima, Yoshiki
Drachman, Brian
Slosky, David
Hüsing-Kabar, Anna
Briseno, Maria Alejandra Gonzalez Duarte
Freimer, Miriam
Luigetti, Marco
Lenihan, Daniel
Polydefkis, Michael
Hanna, Mazen
Nienhuis, Hans
Gottlieb, Stephen
Nicolau, Jose Nativi
Inamo, Jocelyn
Emdin, Michele
Azevedo, Olga
Brunkhorst, Robert
Miller, Edward
Warner, Alberta
Barroso, Fabio Adrian
Press, Rayomand
Hummel, Scott
Beamud, Francisco Munoz
Mazzeo, Anna
Gentile, Luca
Low, Soon Chai
Badelita, Sorina
Quan, Dianna
Tauras, James
Zivkovic, Sasa
Van Cleemput, Johan
Moelgaard, Henning
Plana, Josep Maria Campistol
Torrón, Roberto Fernandéz
Sarswat, Nitasha
Murali, Srinivas
Mueller, Christopher
Fine, Nowell
Darstein, Felix
Adams, David
Dori, Amir
Obici, Laura
Cirami, Calogero Lino
Misawa, Sonoko
Shah, Sanjiv
Tschoepe, Carsten
Davila, Lucia Galan
Oh, Jeeyoung
Parman, Yesim
Marburger, Tessa
Ralph, Jeffrey
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey
https://doi.org/10.1007/s40120-021-00267-y
Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
https://doi.org/10.1007/s40119-022-00265-7
Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS
https://doi.org/10.1007/s40119-021-00226-6
Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey
https://doi.org/10.1007/s40119-023-00344-3
A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy
https://doi.org/10.1080/13506129.2019.1643714
The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology
https://doi.org/10.1185/03007995.2012.754349
THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis
https://doi.org/10.1185/03007995.2012.754348
Funding for this research was provided by:
Pfizer
Article History
Received: 10 September 2023
Accepted: 21 November 2023
First Online: 20 December 2023
Conflict of Interest
: Juan González-Moreno reports speaker fees from Akcea, Alnylam, and Pfizer. Angela Dispenzieri reports research grants from Alnylam, Celgene, Janssen, Millennium, and Pfizer; funding for meeting expenses (travel) from Pfizer; and advisory board fees from Akcea and Intellia. Martha Grogan reports grants and advisory board/consultancy fees paid to her institution from Alnylam, Eidos, Pfizer, and Prothena. Teresa Coelho served as a medical advisor for Pfizer, without honoraria; and reports funding for meeting expenses (travel, accommodation, registration) from Pfizer. Ivailo Tournev reports research funding, honoraria for presentations, and advisory board fees from Alnylam, Pfizer, and Pharma Pro. Márcia Waddington-Cruz reports research funding, consulting fees, and travel support for advisory boards and meetings from FoldRx Pharmaceuticals and Pfizer. Jonas Wixner reports consulting fees and travel support for lectures and advisory boards from Alnylam and Pfizer; and consulting fees from Akcea. Igor Diemberger reports research funding and speaker fees from Daiichi Sankyo and Pfizer (outside scope of present research). Pablo Garcia-Pavia reports speaker fees from Akcea, Alnylam, Eidos, and Pfizer; consulting fees from Alnylam, Akcea, AstraZeneca, Eidos, Neurimmune, and Pfizer; and research/educational support to his institution from Alnylam, Eidos, and Pfizer. Doug Chapman, Pritam Gupta, Oliver Glass, and Leslie Amass are full-time employees of Pfizer and hold stock and/or stock options.
: All THAOS sites received ethical or institutional review board approval before patient enrollment, and each patient provided written informed consent. The study followed the Good Pharmacoepidemiology Practice guidelines and the principles of the Declaration of Helsinki. The study was approved at the primary site in this analysis by Comité de Etica de la Investigación de las Illes Balears (CEIM-IB).